Japanese scientists are reportedly set to start human trials for a drug that can regrow teeth. All being well, the clinical trial will start next year and a tooth regeneration therapy could be ready for people with holey smiles as early as 2030, according to Japanese media.

Back in 2021, a team from the Graduate School of Medicine at Kyoto University published promising research that showed a protein called USAG-1 limits the growth of teeth in mice. By turning off the gene that codes for the production of the protein, the mice were able to freely regrow their teeth.

They were then able to create a neutralizing antibody drug therapy that was able to block the protein’s function, stimulating the mice into growing new sets of teeth. Later experiments showed the same benefits in ferrets, which have a more similar dental pattern to humans.

A speaker comprising tiny robots can deploy multiple microphones to create speech zones that allow it to separate and mute conversations.

A team of researchers in Japan claims to have figured out a way to translate the clucking of chickens with the use of artificial intelligence.

As detailed in a yet-to-be-peer-reviewed preprint, the team led by University of Tokyo professor Adrian David Cheok — who has previously studied sex robots — came up with a “system capable of interpreting various emotional states in chickens, including hunger, fear, anger, contentment, excitement, and distress” by using “cutting-edge AI technique we call Deep Emotional Analysis Learning.”

They say the technique is “rooted in complex mathematical algorithms” and can even be used to adapt to the ever-changing vocal patterns of chickens, meaning that it only gets better at deciphering “chicken vocalizations” over time.

A trio of scientists who developed the combination drug Trikafta are among the winners of five major awards in life sciences, physics and mathematics.

While other therapeutics have helped people and other animals avoid organ rejection, this one appears to trigger fewer dangerous side effects.

The company’s 3D displays have successfully ‘holoported’ products, court witnesses, and even Captain Kirk from one place to another.

Johns Hopkins University (JHU) researchers have developed an experimental brain cancer treatment that not only cured 100% of mice that received it, but also trained their immune systems to fight future cancers.

The challenge: Glioblastoma is a rare but aggressive type of brain cancer — only 5% of patients live for more than five years after they’re diagnosed, and the average survival time is just 12–18 months. It is considered the deadliest kind of cancer.

The standard glioblastoma treatment regimen starts with surgery to remove as much of the tumor as possible. After that, patients typically undergo chemo or radiation therapy to kill lingering cells.

Just four months after the groundbreaking surgery, the patient was able to feel the touch of his sister’s hand.

Say hello to ionocaloric cooling. It’s a new way to lower temperatures with the potential to replace existing methods of chilling things with a process that is safer and better for the planet.

Typical refrigeration systems transport heat away from a space via a gas that cools as it expands some distance away. As effective as this process is, some of the choice gases we use are particularly unfriendly to the environment.

There is, however, more than one way a substance can be forced to absorb and shed heat energy.

In a high-tech laboratory, somewhere in San Francisco, sits a comma-shaped piece of metal that aims to change how the world sees the weather. The structure dominates the room. The horizontal part softly curves upwards until it’s taller than a person, with ridges that stretch from top to bottom. You’d be forgiven for thinking it’s a piece of modern art.

In fact, it is art, but it’s also much more than that. It’s an AI-powered, data-processing powerhouse from a startup called Atmo, and it could democratize weather forecasting, putting every country on a level meteorological playing field for the first time.